tirzepatide rhabdomyolysis for Weight Loss Retatrutide vs Tirzepatide: Comprehensive Comparison

Ozempic label provides placebo-controlled adverse reaction rates for common events (5%) dominated by GI symptoms (dose-related increases in nausea, vomiting, diarrhoea, constipation/abdominal pain)

A meta-analysis including EMPA-REG OUTCOME (empagliflozin), CANVAS Program (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), CREDENCE (canagliflozin) and VERTIS CV (ertugliflozin) demonstrated that SGLT2 inhibitors reduced MACE by 10% (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.850.95) and hospitalization for heart failure by 32% (HR 0.68, 95% CI 0.610.76) compared to placebo [6]

Early work, including in the Journal of Medicinal Chemistry, has mapped these relationships to guide the design of next-generation NNMT inhibitors

What Makes Our Treatment Different